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Abstract
Rationale Cytochrome P450 enzymes are important in the
metabolism of antidepressants. The highly polymorphic na-
ture of these enzymes has been linked to variability in antide-
pressant metabolism rates, leading to hope regarding the use
of P450 genotyping to guide treatment. However, evidence
that P450 genotypic differences underlie the variation in treat-
ment outcomes is inconclusive.
Objectives We explored the links between both P450 geno-
type and serum concentrations of antidepressant with antide-
pressant side effects, using data from the Genome-Based
Therapeutic Drugs for Depression Project (GENDEP), which
is a large (n=868), pharmacogenetic study of depressed indi-
viduals treated with escitalopram or nortriptyline.
Methods Patients were genotyped for the enzymes CYP2C19
and CYP2D6, and serum concentrations of both antidepres-
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sant and primary metabolite were measured after 8 weeks of
treatment. Side effects were assessed weekly. We investigated
associations between P450 genotypes, serum concentrations
of antidepressants and side effects, as well as the relationship
between P450 genotype and study discontinuation.
Results P450 genotype did not predict total side effect burden
(nortriptyline: n=251, p=0.5638, β=−0.133, standard error
(SE)=0.229; escitalopram: n=340, p=0.9627, β=−0.004,
SE=0.085), study discontinuation (nortriptyline n=284, hazard
ratio (HR)=1.300, p=0.174; escitalopram n=376, HR=0.870,
p=0.118) or specific side effects. Serum concentrations of an-
tidepressant were only related to a minority of the specific side
effects measured: dry mouth, dizziness and diarrhoea.
Conclusions In this sample where antidepressant dosage is ti-
trated using clinical judgement, P450 genotypes do not explain
differences between patients in side effects with antidepres-
sants. Serum drug concentrations appear to only explain vari-
ability in the occurrence of a minority of specific side effects.
Keywords Antidepressant .Pharmacogenetics .Sideeffects .
Drugmetabolism . Cytochrome P450 enzymes
Introduction
Cytochrome P450 enzymes play a key role in the metabolism
of antidepressant drugs into less active compounds. But drug
metabolism rates vary between individuals, resulting in
differences between patients in terms of antidepressant serum
concentrations (Reis et al. 2009).
It has been shown that one of the causes of this variability in
rates of antidepressant metabolism are the genotypic differ-
ences seen in the cytochrome P450 (P450) enzymes (Dahl
et al. 1996; Grasmäder et al. 2004; Hodgson et al. 2014;
Huezo-Diaz et al. 2012; Murphy et al. 2001; Rudberg et al.
2008). Kirchheiner et al. used this evidence to suggest
genotype-based adjustments to dosage that would counter these
differences (Kirchheiner et al. 2001; Kirchheiner et al. 2004).
It has been proposed that the variation in drug metabolism
rates, and resultant variation in serum concentrations of anti-
depressant might play a role in whether or not antidepressant
treatment is successful (Ingelman-Sundberg 2004) and go
some way to account for the variability that is seen in out-
comes between patients who are treated with antidepressants
(Trivedi et al. 2006).
In particular, low rates of drug metabolism will lead to
higher levels of antidepressant, and this could potentially ex-
plain why some individuals report high levels of antidepres-
sant side effects. Side effects play an important role in clinical
decision-making when prescribing antidepressants; and ad-
verse drug reactions are frequently cited by patients as a rea-
son for discontinuing antidepressant treatment (Bull et al.
2002). As would be expected, inadequate antidepressant treat-
ment results in increased levels of relapse (Kennedy et al.
2002) as well as increased health costs (Masand, 2003).
Therefore, it is important to try and understand the causes of
antidepressant side effects and treatment discontinuation.
Additionally, there has been interest in the potential use of
P450 genotyping to personalize antidepressant treatment, par-
ticularly in light of FDA approval of the AmpliChip CYP450
Test (de Leon 2006). However, a systematic review in 2007
indicated that there was little evidence to support clinical util-
ity of P450 genotyping in depression, with a number of studies
being underpowered (Matchar et al. 2007).
More recently, two reports have been published examining
P450 genetic prediction of response and tolerance to antidepres-
sant treatment in the large US-based multicentre Sequenced
Treatment Alternatives to RelieveDepression (STAR*D) study.
Whilst one report found no evidence of association with either
outcome amongst patients taking citalopram (Peters et al.
2008), a more recent paper based on the same data (but limiting
the analysis to non-Hispanic Caucasians) concluded that there
was evidence of a link between P450 genotype and both toler-
ance and remission (Mrazek et al. 2011).
In Genome-Based Therapeutic Drugs for Depression
(GENDEP; a European pharmacogenetic study where patients
received either nortriptyline or escitalopram), we found no
evidence for a relationship between treatment response and
P450 genotype (Hodgson et al. 2014). In light of the potential
impact of adverse drug reactions in determining treatment
outcomes (Bull et al. 2002), in this paper, we wish to extend
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this work to also examine the potential links between rates of
drug metabolism and antidepressant side effects.
A range of different adverse drug reactions (ADRs) are
observed with antidepressant medications, each with differing
pharmacological underpinnings. Therefore, we considered
both a measure of overall side effect burden, as well as the
relationship between drug metabolism and each specific
ADR. Additionally, we looked at drug metabolism rates in
two ways: firstly, using genotypic information from the
P450 enzymes of relevance, and secondly, using serum con-
centrations of drug, which allow us to capture the combined
effects of both genetic and environmental influences on drug
metabolism rates. Finally, we explored the association be-
tween P450 genotype and study drop out, as an additional
measure of treatment tolerability.
Methods
Sample
The GENDEP (Genome-Based Therapeutic Drugs for
Depression) project is a European, multicentre, open-label anti-
depressant pharmacogenetic project. The complete GENDEP
cohort (Tansey et al. 2012; Uher et al. 2009b) included 868
treatment seeking adults (19–72 years, 63 % females) diagnosed
with moderate to severe unipolar depression, established using
the Schedules for Clinical Assessment in Neuropsychiatry
(SCAN) interview (Wing et al. 1998). Exclusion criteria were
personal or family history of bipolar disorder or schizophrenia
and/or active substance dependence. To minimize population
stratification, all patients were of White European ancestry.
We randomly allocated patients with no contraindications to
receive either nortriptyline (50–150 mg daily) or escitalopram
(10–30 mg daily). A protocol-driven flexible dosing scheme
was used. Nortriptyline is a tricyclic antidepressant with pre-
dominantly noradrenergic action, whilst escitalopram is a high-
ly selective serotonin reuptake inhibitor. Patients with contra-
indications for one drug were offered the other antidepressant.
We measured the severity of depressive symptoms weekly,
with the Montgomery-Åsberg Depression Rating Scale
(MADRS; Montgomery and Asberg 1979). Prior to treatment,
mean scores on the MADRS were 28.76 (SD=6.78). GEND
EP was approved by ethics boards in all participating centres
and all participants provided written consent after the proce-
dures were explained. GENDEP is registered at EudraCT (no.
2004-001723-38, http://eudract.emea.europa.eu) and ISRCTN
(no. 03693000, http://www.controlled-trials.com).
Side effect measurements
Side effects were measured on a weekly basis using the self-
report Antidepressant Side Effect Checklist (ASEC;
Supplementary Materials), which has been shown to correlate
well with the interview-rated UKU (Lingjaerde, Ahlfors et al.
1987; Uher et al. 2009a). The ASEC was also administered
prior to treatment, to capture any pre-existing symptoms.
TheASECmeasures a total of 21 side effects. Although each
item on the ASEC is rated on a 4-point scale (0, absent; 1, mild;
2, moderate; 3, severe), moderate and severe ratings were un-
common (Uher et al. 2009a). Therefore, the 4-point scale was
collapsed to give ratings of presence or absence of each ADR.
We considered side effects in two ways. Firstly, we calcu-
lated the total number of ADRs experienced each week, to
give a measure of the overall side effect burden for the patient.
Secondly, we examined the weekly presence or absence of
each individual side effect separately, to investigate ADR-
specific effects.
Cytochrome P450 enzyme genotyping
Blood samples were buffered in an EDTA solution and a stan-
dard protocol was used for DNA extraction (Freeman et al.
2003). We genotyped all patients using the Roche AmpliChip
P450 (Roche Molecular Diagnostics, Alameda, CA, USA), a
micro-array that measures 33 variants in CYP2D6 and 2 var-
iants in CYP2C19; In addition, the common *17 allele ob-
served withinCYP2C19 (Sim et al. 2006) was also genotyped,
using a TaqMan SNP genotyping assay on the 7900HT se-
quence detection system (Applied Biosystems, CA, USA).
Genotypes were determined using SDS software (Applied
Biosystems). After genotyping, allelic variation was
categorised using standard nomenclature for the P450 genes.
We used four categories to classify CYP2D6 genotypes: poor
(PM), intermediate (IM), extensive (EM) or ultrarapid (UM)
metabolisers (Rebsamen et al. 2009). For CYP2C19, we used
six categories: poor (PM), intermediate (IM), intermediate
plus (IM+), extensive (EM), extensive plus (EM+) or ultra-
rapid (UM) metabolisers (Mrazek et al. 2011).
We examined CYP2C19 as the relevant P450 genotype in
the escitalopram-specific analyses, with CYP2D6 genotype
included as a fixed effect covariate given the smaller reported
role of the CYP2D6 enzyme (Olesen and Linnet 1999). We
considered CYP2D6 as the relevant P450 genotype in the
nortriptyline-specific analysis. We also controlled for the use
of relevant P450-inhibiting co-medications.
Co-medication
There are a number of commonly prescribed medications
which are known to act as inducers or inhibitors of the P450
enzymes. In GENDEP, each patient reported any medications
taken that were additional to the prescribed antidepressant. We
categorised these co-medications using the FDA classification
of in vivo inhibitors or inducers (FDA 2011). In the week that
we took the blood sample for the measurement of serum
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levels, 5.81 % of patients with serum concentration data re-
ported taking a CYP2C19 and/or CYP2D6 inhibiting drug,
but no patients reporting taking CYP2C19- and/or CYP2D6-
inducing drugs. A list of these reported cytochrome P450-
inhibiting co-medications can be found in Supplementary
Materials.
Serum measurements
After 8 weeks of antidepressant treatment, we drew blood
from patients in order to measure serum concentrations of
both the antidepressant taken (nortriptyline or escitalopram)
and its primary metabolite (10-hydroxynortriptyline or
desmethylcitalopram). By this point, steady state serum con-
centrations would have been achieved (Hiemke and Hartter
2000; Linder and Keck 1998). All serum analyses were per-
formed at the Department of Clinical Biochemistry, Kings
College Hospital, London (UK).
Details are published elsewhere (Hodgson et al. 2014), but
briefly, escitalopram, desmethylcitalopram, nortriptyline and
total 10-hydroxynortriptyline were measured using achiral
turbulent flow liquid chromatography (Couchman 2012).
Detection was by tandem mass spectrometry (MS/MS)
(TSQ Vantage, Thermo Fisher Scientific, Hemel Hampstead,
UK). The cis- and trans-isomers of 10-hydroxynortriptyline
were resolved and assay calibration was based on the cis-iso-
mer. Sample preparation in both cases was by protein precip-
itation. The method used was fully validated according to
FDA guidelines (FDA 2001).
Four measures of serum concentration were considered in
the study; concentration of drug, concentration of primary
metabolite, ratio of metabolite to drug concentration, and total
concentration of drug plus metabolite. Each of these serum
measurements were standardised for ease of interpretation,
with a mean of 0 and a standard deviation of 1. Figure 1 shows
the number of patients where serum measurements and/or
P450 genotypes were available.
Statistical analysis
Given the different pathways for the metabolism of
escitalopram and nortriptyline, all analyses were performed
in a drug-specific manner. Previous analyses in this sample
have established a relationship between P450 genotype and
serum for both escitalopram and nortriptyline (more active
forms of enzyme are associated with lower levels of antide-
pressant drug). The aim of this analysis was to consider how
P450 genotype and serum concentrations of antidepressant
might relate to the presence of ADRs.
Asweekly measurements of ADRswere available, we used
these repeated measures in our statistical model, with a Huber-
White sandwich estimator of variance (Williams 2000), which
provides standard errors that are robust to intra-individual cor-
relations and so, relaxes the assumption of independent obser-
vations (Kent 1982).
Associations with total ADR burden were tested using linear
models, whilst the weekly presence/absence of each specific
ADR was examined using logistic models. When considering
the specific ADRs, in order to correct for the 21 different out-
comes, a Bonferroni correction for multiple hypothesis testing
was applied; only associations where p<0.002381 were con-
sidered significant (0.05/21=0.002381).
To ensure that reports of ADRswere not confounded by the
severity of depression, MADRS scores were entered as a co-
variate in all analyses, along with baseline reports of ADRs,
age, sex, linear and quadratic effects of time and centre of
recruitment. When testing P450 genotype as a predictor, both
P450-inhibiting medication and dose of antidepressant were
used as covariates. Analyses of serum concentrations of anti-
depressants were performed in two stages. For the initial anal-
ysis of serum measurements, dose was not included as a co-
variate. We then performed secondary analyses with dose as a
covariate for any ADRs which showed significant association
with serum concentration of antidepressant, to probe the na-
ture of the serum-side effect association.
Finally, P450 genotype was considered as a predictor of time
to study discontinuation, using a survival Cox proportional
hazards model. Covariates of age, sex, centre, baseline depres-
sion and baseline total ADR score were included in the model.
Power calculations
The smallest sample size included in these analysis was the
168 patients taking nortriptyline with both serum and dose
information available. Using G*Power (Faul et al. 2007), we
calculated that in this sample, it is possible to detect an effect
size explaining 4.7 % of the variance in outcome with 80 %
power, at a p value threshold of 0.05. This corresponds to 0.52
points on the ASECwhen measuring total ADR burden.When
assessing study drop out, the power calculation for the survival
model was conducted within STATA, using the drug-specificFig. 1 Diagram describing GENDEP sample
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rate of study drop-out. In the nortriptyline-specific analysis,
hazard ratios of 0.64 (or 1.56) could be detected at p<0.05 with
80 % power. For the escitalopram-specific analysis, hazard
ratios of 0.78 (or 1.28) could be detected.
Results
Genotypic frequencies in this sample were typical of a
Caucasian population (see Supplementary Materials for
details), and P450 genotype was unrelated to age, sex, centre
of recruitment or dose of antidepressant prescribed.
Serum concentrations of antidepressant are shown in
Table 1. Concentrations of drugs and primary metabolites
were unrelated to age in this sample. Females had significant
higher concentration of escitalopram (M=31.56 μg/L, SD=
19.933) than males (M=25.56 μg/L, SD=16.44); t(273)=
−2.47, p=0.014. No significant differences were observed be-
tween males and females for desmethylcitalopram, nortripty-
line and 10-hydroxynortriptyline concentrations. As expected,
dose across the study was significantly related to serum levels
of antidepressant measured at week 8 (see Supplementary
Materials). There were also differences between centre of re-
cruitment in terms of serum concentrations of antidepressant
(see Supplementary Materials). Figure 2 shows the pattern of
weekly overall ADR burden, whilst the frequency of each
individual ADR is shown the Supplementary Materials.
Serum measurements were unavailable for some patients (as
shown in Fig. 1). Amongst patients taking escitalopram with
ADR ratings, total ADR burden was unrelated to whether serum
measurements of antidepressant concentration were available or
not. However, total ADR burden was associated with whether
serummeasurements were available amongst patients taking nor-
triptyline (b=1.137, t(302)=2.85, p=0.005); higher ADRburden
was seen in those patients without serum measurements.
Overall ADR burden
The total number of ADRs was not predicted by P450 geno-
type. Given the previously observed association between
P450 genotype and antidepressant tolerance when contrasts
were made between PM vs all other genotypes (Mrazek
et al. 2011), we also performed these comparisons in this
sample, but still found no association for patients taking either
nortriptyline or escitalopram. Additionally, serum concentra-
tions of antidepressant did not predict total number of ADRs
for either group. Results are shown in Table 2.
Specific ADRs
P450 genotype did not predict the presence of any specific
ADRs, for patients taking either nortriptyline or escitalopram.
There was also no significant association between serum con-
centrations of antidepressant and the majority of specific
ADRs. However, for all patients (taking nortriptyline or
escitalopram), a significant association was seen between
dry mouth and serum concentrations of both drug and metab-
olite, as well as total concentration of antidepressant (Table 3).
Additionally, amongst patients taking escitalopram, signif-
icant associations were observed between diarrhoea and the
ratio of metabolite to drug (n=203, obs=2210, p=4.96×10−4,
odds ratio (OR)=0.597, SE=0.088), as well as between diz-
ziness and the concentration of metabolite (n=202, obs=
Table 1 Measured serum concentrations (μg/L) of antidepressant drug
and primary metabolite
Drug Measure Number Mean St Dev
Escitalopram Escitalopram 275 29.60 19.04
Desmethylcitalopram 205 11.25 5.21
Nortriptyline Nortriptyline 184 93.35 59.28
10-hydroxynortriptyline 180 67.99 53.37
0
Fig. 2 Total ADR burden per week, by drug. (Box outlines lower to
upper quartiles with median markers, whiskers show 5th to 95th
percentile, outliers are indicated by hollow circles)
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2197, p=3.28×10−5, OR=1.564, SE=0.168). Full results for
all 21 ADRs tested are shown in the SupplementaryMaterials.
Dose-adjusted analysis of significant associations
To probe the nature of the significant association between
serum concentrations and these specific ADRs, we performed
a secondary analysis, looking at the dose-independent rela-
tionships. When the effect of dose was removed, dry mouth
was significantly associated with metabolite and total serum
concentrations in patients taking nortriptyline (Table 3). The
associations for diarrhoea with ratio of metabolite to drug (n=
188, obs=2028, p=0.0013, OR=0.632, SE=0.090) and diz-
ziness with metabolite concentration (n=188, obs=2025, p=
1.05 × 10−6, OR= 1.658, SE = 0.172) in patients on
escitalopram also remain significant when covarying for dose.
Study discontinuation
P450 genotype was unrelated to study discontinuation, for
patients taking either escitalopram (n=376, hazard ratio=
0.870, p=0.118), or nortriptyline (n=284, hazard ratio=
Table 2 CYP450 genotype and serum levels of antidepressant as predictors of overall ADR burden
Antidepressant Predictor Number obs p value coeff SE (robust)
Nortriptyline CYP2D6 genotype 251 2183 0.5638 −0.133 0.229
CYP2D6; poor metabolisers vs all other genotypes 251 2183 0.5527 −0.321 0.541
Serum concentration nortriptyline 184 1890 0.8534 −0.029 0.154
10-hydroxynortriptyline 180 1847 0.7323 0.063 0.183
ratio (10-hydroxynortriptyline: nortriptyline) 178 1832 0.1895 0.232 0.176
total (nortriptyline + 10-hydroxynortriptyline) 178 1832 0.7975 0.044 0.170
Escitalopram CYP2C19 genotype 340 3332 0.9627 −0.004 0.084
CYP2C19; poor metabolisers vs all other genotypes 340 3332 0.5791 −0.361 0.649
Serum concentration escitalopram 275 2978 0.0852 0.250 0.145
desmethylcitalopram 205 2242 0.1587 0.248 0.175
ratio (desmethylcitalopram: escitalopram) 204 2230 0.6945 −0.066 0.167
total (escitalopram + desmethylcitalopram) 204 2230 0.1155 0.260 0.165
Table 3 Dry mouth and serum concentration of antidepressant
(A) Primary analysis
Antidepressant Serum concentration Number obs p value OR SE (robust)
Nortriptyline nortriptyline 184 1888 0.0023 1.826 0.362
OH-nortriptyline 180 1845 1.20E-04 2.100 0.405
ratio (OH-nortriptyline/nortriptyline) 178 1830 0.0406 1.406 0.234
total (nortriptyline + OH-nortriptyline) 178 1830 4.97E-05 2.284 0.465
Escitalopram escitalopram 275 2969 6.69E-04 1.480 0.170
desmethylescitalopram 205 2233 0.0018 1.420 0.159
ratio (desmethylcitalopram/citalopram) 204 2221 0.6162 0.931 0.133
total (citalopram + desmethylcitalopram) 204 2221 0.0012 1.496 0.186
(B) Secondary analysis; adjusting for effects of dose
Antidepressant Serum concentration Number obs p value OR SE (robust)
Nortriptyline nortriptyline 168 1698 0.0331 1.841 0.345
OH-nortriptyline 164 1664 0.0011 1.841 0.345
ratio (OH-nortriptyline/nortriptyline) 163 1652 0.0459 1.423 0.251
total (nortriptyline + OH-nortriptyline) 163 1652 0.0016 2.082 0.484
Escitalopram escitalopram 255 2715 0.0107 1.391 0.180
desmethylescitalopram 190 2050 0.0189 1.326 0.159
ratio (desmethylcitalopram/citalopram) 189 2038 0.9823 1.003 0.148
total (citalopram + desmethylcitalopram) 189 2038 0.0319 1.358 0.194
Significant results in bold
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1.300, p=0.174). The (non-significant) hazard ratios given
indicate the increase in relative risk of discontinuation, mov-
ing from less to more active P450 genotypes.
Discussion
Cytochrome P450 genotype did not predict overall side effect
burden, any of the 21 specific ADRs measured or study dis-
continuation in this sample. Further investigation, using serum
concentration measures indicated that for both overall burden
and the majority of specific ADRs, there was also no relation-
ship with circulating levels of antidepressant. Exceptions to
this general pattern were observed for dry mouth, dizziness
and diarrhoea.
In the case of dry mouth, higher serum concentrations of
antidepressant were linked to higher risk of the side effect for
both escitalopram and nortriptyline. After adjusting for the
influence of dose on serum concentration, the association with
both metabolite and total serum concentration remained sig-
nificant for patients taking nortriptyline. Amongst patients
taking escitalopram, associations of diarrhoea with the ratio
of metabolite to drug, and dizziness with concentration of
metabolite were observed; both of these associations also re-
main significant after adjusting serum concentrations for pre-
scribed dose of escitalopram. The absence of P450 genotypic
association for each of these specific side effects indicates the
importance of other factors that influence drug metabolism,
beyond genetic variation in the cytochrome P450 enzymes.
When addressing the potential clinical impact for these
associations with serum concentrations, it is important to con-
sider baseline incidence of these specific ADRs; both diar-
rhoea and dizziness are rare side effects (with prevalence be-
low 10 % of reports from patients taking escitalopram in this
sample). This contrasts with dry mouth, which occurs in more
than 70 % of reports from patients taking nortriptyline in this
sample.
Despite the rarity of dizziness as a side effect to antidepres-
sant treatment, it is nevertheless interesting to note that dizzi-
ness one of the few specific ADRS which shows significant
association with treatment discontinuation in both the GEND
EP (Uher et al. 2009a) and GenPod (Crawford et al. 2014)
antidepressant treatment samples.
The failure to observe any association between P450 geno-
type and overall number of side effects holds even when col-
lapsing genotype categories to compare poor metabolisers
against all other genotypes; this is in contrast to a previous
report examining tolerance to citalopram (Mrazek et al. 2011).
However, power calculations suggest that the analyses pre-
sented here are sufficiently powered to detect any effects of
a magnitude that would be clinically useful.
Furthermore, this study not only consider two different
antidepressants (escitalopram and nortriptyline, which have
divergent mechanisms of action), but also incorporate addi-
tional information on serum concentrations of antidepressant.
This allows us to examine effects on drug metabolism beyond
the genetic variability in P450 enzymes. However, even using
this information, whilst three specific ADRs show evidence of
association in drug-specific groups, we still fail to observe a
link between rates of antidepressant metabolism and overall
side effect burden for either escitalopram or nortriptyline.
The results presented here indicate that drug metabolism
rates (and in particular P450 genotypes) are not of predictive
of antidepressant side effects. But this should not be entirely
surprising given what is known about the complexity of
ADRs associated with ant idepressant t reatment .
Pharmacokinetic factors beyond the cytochrome P450 en-
zymes (for example, the transportation of drug across the
blood-brain barrier via P-glucoprotein 1), pharmacodynamic
factors and the severity of depressive symptoms (Uher et al.
2009a) could all exert an influence on an individual’s likeli-
hood of experiencing side effects with antidepressant treat-
ment, indicating the antidepressant side effects are complex
and multifactorial in nature. So, whilst drug levels may be
linked to dry mouth, dizziness and diarrhoea, in order to ac-
curately predict the majority of side effects, more complex and
multifactorial modelling is required.
Nevertheless, all conclusions must be drawn within the
context of the study design. In GENDEP, patients received
treatment according to a flexible dosing protocol, where both
treatment response and side effects could be used by clinicians
to inform dose alterations throughout the study. This means
that the doses received by patients were adjusted in response
to treatment outcomes as the study proceeded. Thus, our con-
clusions indicate the extent to which data on P450 genotypes
and serum concentrations of antidepressants are associated
with the variation in ADRs and treatment discontinuation seen
across 12 weeks, within a sample under clinical observation.
Therefore, we conclude that in this sample, where antide-
pressant dosage is monitored by clinicians and adjusted using
their judgement, P450 genotypes are not predictive of
treatment-associated side effects, as measured by overall side
effect burden, specific ADRs or study discontinuation.
However, there is some evidence that drug metabolism rates
may play a role in the occurrence of dizziness and diarrhoea
for patients taking escitalopram and of dry mouth for patients
taking nortriptyline.
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